(CPHI) China Pharma Holdings - Ratings and Ratios

China Pharma Holdings, Inc. (NYSE MKT: CPHI) is a specialty pharmaceutical company focused on developing, manufacturing, and distributing generic and branded pharmaceutical, biochemical, and healthcare products in the Peoples Republic of China. The company specializes in producing injectables, tablets, capsules, and oral solutions targeting cardiovascular, cerebrovascular, and neurological conditions, among others. Its product portfolio includes treatments for memory decline, cerebral thrombosis, hypertension, and infectious diseases, as well as supplements and personal protective equipment (PPE) such as sanitizers and masks.

The company operates through a network of distributors, sales offices, and representatives, ensuring broad access to its products across China. Its offerings include prescription drugs, over-the-counter medications, and health supplements, addressing a wide range of medical needs. With a market capitalization of $3.69 million and a price-to-book ratio of 0.68, the stock is currently trading at $0.23, with a 20-day average volume of 590,214 shares. The 20-day, 50-day, and 200-day moving averages are aligned at $0.22 and $0.23, respectively, indicating stable price action. The average true range (ATR) of $0.03 reflects low volatility.

3-Month Forecast: Based on , the stock is expected to remain range-bound between $0.20 and $0.25, with minimal upside potential due to low volatility and a flat moving average trend. The suggests limited growth prospects, as indicated by a negative return on equity (-72.67%) and a low price-to-sales ratio (0.80). However, the companys focus on essential healthcare products may provide near-term stability. Investors should monitor for potential catalysts, such as new product approvals or strategic partnerships, to drive upward momentum.